No Data
Cutia Therapeutics Obesity Drug Reaches Meaningful End to Clinical Trial
Kedy-B (02487.HK): CU-20401 (recombinant mutated collagenase) achieved the main endpoint in phase II clinical trials for submental fat accumulation treatment.
On November 29, Gelonhui announced that the group's potential class 1 new drug CU-20401 (recombinant mutated collagenase) conducted a Phase II clinical trial for the treatment of submental fat accumulation in China has obtained top-line data. The data shows that the clinical trial has achieved the primary research endpoint, with results that are statistically significant and clinically meaningful. This clinical trial is a multicenter, randomized, double-blind, and placebo-controlled trial designed to evaluate the effectiveness and safety of CU-20401 in patients with moderate to severe submental fat accumulation, with a total of 108 subjects enrolled. The analysis results show.
Cutia Therapeutics Phase III Trial for Skin Treatments Presented in Annual CDA Meeting
Kedi-B (02487.HK): The results of the phase III clinical trials for CU-40102 (topical finasteride spray) and CU-30101 (topical lidocaine-dinocaine cream) in china were announced at the 19th CDA Annual Meeting.
On November 28, Gelonghui reported that Kedi-B (02487.HK) announced the results of the Phase III clinical trials in China for its products for the treatment of androgenetic alopecia, CU-40102 (topical finasteride spray), and CU-30101 (topical lidocaine dentocaine cream) for skin epidermal surgeries, were released in the form of an electronic poster at the 19th Annual Meeting of the Dermatology Physicians of the Chinese Medical Association and the National Conference on Aesthetic Dermatology ("CDA Annual Meeting"). The group's research achievements have been selected for the CDA annual meeting two consecutive times, representing the group's industry influence and cutting-edge standards in the field of dermatology.
Hong Kong stocks movement | CUTIA-B (02487) rises over 4% as CU-10201 (4% minocycline foam agent for external use) receives approval for listing from the National Medical Products Administration.
CUTIA-B (02487) rose over 4%, reaching 4.14% increase as of the time of this report, priced at 9.8 Hong Kong dollars, with a transaction value of 4.0826 million Hong Kong dollars.
SciClone-B (02487.HK): CU-10201 (Topical 4% Minocycline Foam) has obtained approval from the National Medical Products Administration for marketing.
Gelonghui, November 12th | Kedebi-B (02487.HK) announced that the group's CU-10201 (topical 4% minocycline foam) has been approved for marketing by the China National Medical Products Administration. CU-10201 is indicated for the treatment of non-nodular moderate to severe acne and is suitable for use by children aged nine and above and adult patients. CU-10201 is the world's first and only approved topical minocycline for the treatment of acne vulgaris, as well as the first topical minocycline to be approved for marketing with priority review and approval by the China National Medical Products Administration.
No Data
